Marshall Wace LLP Makes New $1.62 Million Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Marshall Wace LLP acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 10,331 shares of the company's stock, valued at approximately $1,618,000.

A number of other hedge funds also recently made changes to their positions in KRYS. Entropy Technologies LP purchased a new position in Krystal Biotech during the fourth quarter valued at approximately $548,000. Janney Montgomery Scott LLC raised its position in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after purchasing an additional 15,545 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Krystal Biotech by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock valued at $19,340,000 after buying an additional 3,727 shares in the last quarter. abrdn plc boosted its holdings in Krystal Biotech by 32.5% in the 4th quarter. abrdn plc now owns 57,033 shares of the company's stock worth $8,935,000 after buying an additional 13,979 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after buying an additional 433 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS traded up $0.47 during midday trading on Friday, reaching $166.16. 228,173 shares of the stock traded hands, compared to its average volume of 294,547. The company's 50 day moving average is $174.92 and its 200 day moving average is $171.22. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The stock has a market capitalization of $4.80 billion, a PE ratio of 55.57 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the business earned $0.30 earnings per share. Krystal Biotech's quarterly revenue was up 116.4% compared to the same quarter last year. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on KRYS shares. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. HC Wainwright increased their price objective on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a report on Monday, April 28th. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Citigroup upped their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $222.71.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).